Introduction
Cells normally contain one or two centrosomes at varying phases of the cell cycle. Centrosome duplication is initiated at late G 1 and continues into S phase (reviewed in Lange, 2002; Rieder et al., 2001; Winey, 1996) . Prior to mitosis, the duplicated centrosomes separate and move to the future poles of spindle in order to form the bipolar spindle, which is essential for equal segregation of chromosomes. Dysregulation of centrosome duplication can cause chromosome aneuploidy and, consequently, lead to malignant transformation. Many human cancers, including highgrade breast cancers, exhibit both centrosome amplification and chromosome aneuploidy (Lingle et al., 1998 (Lingle et al., , 2002 Pihan et al., 1998) , providing a strong link between abnormalities in centrosome duplication and tumorigenesis.
Breast cancer suppressor gene 1, BRCA1, was mapped in 1990 (Hall et al., 1990) and cloned four years later (Miki et al., 1994) . Mutations in BRCA1 have also been found in approximately 40% of familial breast cancer and most of combined familial breast and ovarian cancers (reviewed in Alberg and Helzlsouer, 1997; Alberg et al., 1999) . BRCA1 contains 24 exons that encode a large protein of 1863 amino acids in humans (Miki et al., 1994) and 1812 amino acids in mice (Lane et al., 1995) . Functions of BRCA1 are a subject of extensive research. It was shown that BRCA1 contains a number of structural motifs that interact directly or indirectly with many proteins with diverse functions (reviewed in Deng and Brodie, 2000) . Consistent with this, mounting evidence indicates that BRCA1 plays essential functions in many biological processes, including transcription activation and repression (Aprelikova et al., 2001; Chai et al., 1999; Chapman and Verma, 1996; Fan et al., 1999; Zhang et al., 1994 Zhang et al., , 1998 Zheng et al., 2001) , cell cycle regulation (Xu et al., 1999b; Yarden et al., 2002) , chromatin remodeling (Bochar et al., 2000; Hu et al., 1999; Ye et al., 2001) , DNA damage repair (Gowen et al., 1998; Moynahan et al., 1999; Scully et al., 1997; Zhong et al., 1999) , and centrosome duplication (Hsu et al., 2001; Xu et al., 1999b) . The essential roles of BRCA1 in cell survival were revealed by the early lethality of BRCA1-null embryos created by gene targeting in mouse (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) . In mutant mice where BRCA1 was selectively disrupted in mammary epithelium using a Cre-loxP approach, mammary tumors developed at low frequency after long latency (Xu et al., 1999a) . Further analysis revealed the involvement of multiple factors in the BRCA1 associated tumorigenesis, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1, as well as down-regulation or loss of p53 and p16 in the majority of tumors Xu et al., 2001) . A significant finding from BRCA1 mutant cells was that the absence of BRCA1 resulted in centrosome amplification (Xu et al., 1999b) . As the centrosome is essential for faithful segregation of chromosomes, it is proposed that one of the mechanisms, through which BRCA1 maintains genetic stability, is through its roles in regulating centrosome duplication (Deng, 2001; Xu et al., 1999b) . This review will examine the evidence for the role of BRCA1 in centrosome duplication.
Targeted deletion of BRCA1 exon 11 results in centrosome amplification
Like human BRCA1 gene (Miki et al., 1994) , mouse BRCA1 encodes two major isoforms due to an alternative splicing at exon 11 (Xu et al., 1999b) . The full length transcript is 7.2 kb and the short one is 3.9 kb due to the lack of exon 11, which is the largest exon and encodes over 60% of amino acids of the protein. Gene targeting studies revealed that BRCA1-null embryos died during early gestation (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) and mutant cells failed to grow even in a p53-null background (Shen et al., 1998) . To overcome the early lethality, Xu et al. (1999a Xu et al. ( , 2001 ) deleted BRCA1 exon 11 from mouse germline and found that the BRCA1 D11/D11 embryos died at E12.5 -18.5 due to wide spread apoptosis, which might be triggered by genetic instability (Xu et al., 1999b . Mouse embryonic fibroblast cells (MEFs) derived from BRCA1 D11/D11 embryos contained the short isoform of BRCA1 and could grow in culture condition, although slower than controls (Xu et al., 1999b) . This is a significant difference between BRCA1 D11/D11 cells and BRCA1-null cells, which fail to grow in vitro (Shen et al., 1998) . Analysing the BRCA1 D11/D11 MEF cells, Xu and colleagues found that about 25% of BRCA1
D11/D11
cells contained more than two centrosomes ( Figure  1b) , instead of only one or two as observed in the control cells (Figure 1a ). In the mitotic phase, these centrosomes formed spindles with multiple poles as evidenced by double-labeling using antibodies to g-and a-tubulin ( Figure 1c ). The multi-polar spindles pulled chromosomes in different directions and led to unequal segregation of chromosomes and micronuclei formation. Consequently, the mutant cells were aneuploid. This study provides genetic evidence implicating BRCA1 in the centrosome duplication process.
BRCA1 interacts with g-tubulin and is associated with the centrosome during mitosis
The first evidence that BRCA1 plays a role in centrosome duplication came from observations that BRCA1 interacts with g-tubulin and is associated with the centrosome during mitosis (Hsu and White, 1998) . Using two distinct BRCA1-specific antibodies for immunofluorescent staining in COS-7 cells, Hsu and White (1998) revealed a unique dot pattern of staining reminiscent of centrosomes in nuclei of mitotic cells (Figure 2 ). This observation was confirmed by coimmunostaining in a number of additional cell lines with antibodies to g-tubulin and pericentrin, both of which are well-known components of the centrosome. They further demonstrated that BRCA1 is associated with g-tubulin isolated from cells arrested in G 2 -M phase.
Recently, Hsu et al. (2001) demonstrated that a piece of DNA in exon 11 of BRCA1, which encodes amino acids from 504 to 803 of the protein, interacted with gtubulin both in vitro and in vivo (Hsu et al., 2001) . They further showed that expression of this fragment in transfected cells could also cause centrosome amplification and mitotic abnormalities. Moreover, this region not only interfered with the interaction between BRCA1 and g-tubulin, but also caused slower cell proliferation and increased apoptosis.
Interestingly, it is the hypophosphorylated, but not the hyperphosphorylated, form of BRCA1 that binds to g-tubulin. Consistently, induction of hyperphosphorylation by okadaic acid, an inhibitor of protein phosphatases type 1 and 2A, reduced association of BRCA1 with g-tubulin and resulted in abnormal (Hsu et al., 2001) . The relationship between BRCA1 phosphorylation and centrosome duplication is currently unclear and will be discussed later.
BRCA1 and its interacting proteins in centrosome duplication
Despite the facts that BRCA1 binds the centrosome and that the lack of BRCA1 exon 11 results in centrosome amplification, it remains to be illustrated how BRCA1 regulates centrosome duplication. One prominent feature of BRCA1 is that it interacts with many proteins that play important roles in multiple biological pathways (reviewed in Deng, 2002; Deng and Brodie, 2000; Venkitaraman, 2002; Zheng et al., 2000) . Some of these, i.e. p53, BRCA2, Rb, CDK2-Cyclin A and CDK2-Cyclin E, are known to play important roles in centrosome duplication (Table 1) . While these observations suggest that BRCA1 does not work alone, the possible relationship between BRCA1 and these interacting proteins in regards to centrosome duplication is currently unknown.
To understand this, it is necessary to review the relationship between CDK2 and p53, the two most well studied BRCA1 interacting proteins, for their roles in centrosome duplication. CDK2 works as a positive regulator for centrosome duplication, as ablation of its function blocks the process (Hinchcliffe et al., 1999; Meraldi et al., 1999) . On the other hand, p53 has been known to negatively regulate centrosome duplication, as absence of p53 results in centrosome amplification (Fukasawa et al., 1996; Tarapore and Fukasawa, 2000) . P53 binds to both duplicated and unduplicated centrosomes. Interestingly, it was shown that CDK2 phosphorylates p53 at S315 (Merrick et al., 2001; Price et al., 1995) . A change of this amino acid from S315A (loss of the phosphorylation site) blocks the binding of p53 to unduplicated centrosomes and significantly disables p53 in regulating centrosome duplication (Tarapore et al., 2001 ). This observation reveals that phosphorylation of p53 by CDK2 is important for p53 function in regulating centrosome duplication. A similar relationship between CDK2 and BRCA1 may be deduced from the following observations. CDK2 was found to phosphorylate BRCA1 (Ruffner et al., 1999) . The phosphorylated form of BRCA1 fails to interact with centrosomes, and hyperphosphorylation of BRCA1 causes centrosome amplification (Hsu et al., 2001) . It is conceivable that the hypophosphorylated form of BRCA1 normally represses centrosome duplication, while the phosphorylation of BRCA1 by CDK2 (or other kinases) inactivates BRCA1 to enable the initiation and/or continuation of the process. This possibility needs to be tested in future studies.
BRCA1 and its downstream target genes in centrosome duplication
Considering that BRCA1 has transcriptional activities (reviewed in Deng and Brodie, 2000; Venkitaraman, 2002; Zheng et al., 2000) it is possible that BRCA1 regulates centrosome duplication through transactivation of centrosome specific genes. So far, two BRCA1 downstream genes, p21 and Gadd45, have been found to play a role in centrosome duplication (Harkin et al., 1999; Hollander et al., 1999; Mantel et al., 1999; Somasundaram et al., 1997) . P21 plays a role in p53 mediated G 1 -S cell cycle checkpoint . Absence of p21 was shown to cause centriole overduplication (Mantel et al., 1999) . Despite the observation that BRCA1 positively regulates p21 expression (Somasundaram et al., 1997) , lack of BRCA1 did not result in the downregulation of p21. Instead, in BRCA1 mutant embryos and MEF cells, expression of p21 was increased (Hakem et al., 1996; Xu et al., 2001) . Thus, it is unlikely that the centrosome amplification observed in BRCA1 mutant cells is due to the loss of p21.
Another BRCA1 downstream target gene that is involved in centrosome duplication is Gadd45 (Fan et al., 2002; Harkin et al., 1999; Jin et al., 2000) . It was shown recently that a loss of function mutation of Gadd45 results in centrosome amplification in about 20% Gadd45 7/7 MEF cells (Hollander et al., 1999) . A plausible explanation is that BRCA1 regulates centrosome duplication through controlling Gadd45 expression. However, we found that in the MEF cells with loss of function of both BRCA1 and Gadd45, about 40% cells contained three or more centrosomes (X Wang and C Deng, unpublished observation). If BRCA1 plays a function only through regulating Gadd45, then the combined mutations of both genes would not be expected to enhance the phenotype. Thus, this observation suggests that the relationship between BRCA1 and Gadd45 in centrosome duplication is not simply epistastic. Instead, it may be involved in parallel, yet interacting pathways.
Summary and future directions
Thus, the interaction of BRCA1 with a number of centrosome interacting proteins, its phosphorylation by CDK2 -Cyclin E, and its synergistic action with Gadd45 are consistent with a view that BRCA1 plays a role in regulating centrosome duplication. However, the exact role of BRCA1 in this process remains to be illustrated. Based on existing knowledge, BRCA1 could be involved in several distinct steps of centrosome duplication (Figure 3 ). It may serve as a switch to control centrosome duplication, as only the hypophosphorylated form of BRCA1 binds to centrosomes and the disruption of BRCA1 results in centrosome duplication. Specifically, in its hypophosphorylated form, BRCA1 binds to centrosomes and represses their duplication, while in the hyperphosphorylated form, it is released from centrosomes to allow the progression of the duplication process. BRCA1 could also play its role in centrosome duplication through regulating expression of its downstream genes, such as p21 and Gadd45 (Figure 3 ).
While the above proposed functions of BRCA1 need further scrutiny, I would like to consider a couple of other possibilities, which argue that BRCA1 does not directly regulate centrosome duplication and that the Figure 3 A working model regarding functions of BRCA1 in centrosome duplication. Centrosome duplication contains four morphological steps, i.e. centriole splitting, centriole duplication, centrosome disjunction, and daughter centrosome separation. This is a precisely regulated process that involves many factors, including p53, p21, CDK2 -CycA/E, E2F, STK-15, Mp-1 kinase, Gadd45, NO38/23 and so on. BRCA1 may serve as a part of this network that regulates centrosome duplication. Specifically, it could inhibit centrosome duplication by binding to g-tubulin in its hypophosphorylated form. The phosphorylation of BRCA1 by CDK2-CycE and/or other kinases causes disassociation of BRCA1 with g-tubulin to allow the continuation of duplication process (Green). BRCA1 could also function by regulating expression of its downstream genes, such as p21 (blue) and Gadd45 (red) amplification of centrosomes in BRCA1 mutant cells may be secondary to other changes in the cell cycle. Recently, when studying a role of Aurora-A (STK-15) in centrosome duplication, Meraldi et al. (2002) demonstrated that a major route for Aurora-A induced centrosome amplification in p53 7/7 cells is through tetraploidization (Meraldi et al., 2002) . The tetraploidization could be caused by mitotic abortion (i.e. a failure in cell division after finishing S phase), therefore, cells return to G 1 with 4N of DNA and two centrosomes. Multiple centrosomes will be observed in these cells in the next round of the cell cycle. They further suggested that many proteins, including BRCA1, could cause centrosome amplification through this route, rather than enhanced centrosome duplication.
Moreover, previous investigations showed that BRCA1 mutant cells proliferated slower and had longer G 1 phase than wild type cells (Xu et al., 1999b . Because centrosome duplication initiates at the end of G 1 phase, and centrosomes could continue to duplicate when cells are arrested at G 1 -S (Balczon et al., 1995) , it is also possible that the prolonged G 1 phase could be a trigger for the extra cycle of centrosome duplication in BRCA1 mutant cells.
All these possibilities are highly testable. For example, cell progression through each phase of the cell cycle and gene expression profiles can be closely monitored. Mitosis entry and exit, metaphase chromosome change, as well as centrosome number could be directly monitored microscopically with time-lapse function if proper markers are used. Future studies should be carefully designed to address these issues. Furthermore, many other genes have been shown to play essential roles in centrosome duplication, such as STK15/BTAK, Mps1p, centrin, E2F, CDK1 -Cyclin B, Nucleophosmin, and SCF (Skp/Culin/F-Box proteins) (reviewed in Hinchcliffe and Sluder, 2001; Lange, 2002; Winey, 1999) . It will be interesting to determine relationships between these proteins and BRCA1 in controlling centrosome duplication and breast tumor formation.
